Page last updated: 2024-08-17

carbostyril and Neoplasms

carbostyril has been researched along with Neoplasms in 130 studies

Research

Studies (130)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (1.54)	18.7374
1990's	10 (7.69)	18.2507
2000's	45 (34.62)	29.6817
2010's	58 (44.62)	24.3611
2020's	15 (11.54)	2.80

Authors

Authors	Studies
Bindu, B; Manikandan, A; Vijayalakshmi, S	1
Anandam, A; Jain, P; Jayshree, BS; Kar, SS; Kumar, N; Rai, A; Raj, VP; Rao, CM; Thomas, S	1
Ambudkar, SV; Chen, ZS; Ji, N; Lei, ZN; Lusvarghi, S; Teng, QX; Wang, JQ; Wu, ZX; Yang, Y	1
Ausekle, E; Ejaz, SA; Iqbal, J; Khan, I; Langer, P; Miliutina, M	1
Chein, RJ; Chen, JJW; Cheng, TR; Chou, TH; Chung, WC; Hong, TM; Lee, TC; Lin, MS; Tsai, ML; Weng, CW; Wong, CH; Yang, PC; Yang, SC	1
Kaiser, J	1
Andrade, CH; Custodio, JMF; D'Oliveira, GDC; Filho, JTM; Junior, PSC; Napolitano, HB; Neves, BJ; Perez, CN; Silveira-Lacerda, EP; Vaz, WF	1
Ashwell, S; Barr, KJ; Campbell, AM; Caravella, JA; Castro, J; Clarke, A; Diebold, RB; Dinsmore, CJ; Ericsson, A; Gotur, D; Gustafson, G; Josephine, HR; Katz, M; Kershaw, M; Lin, J; Lu, W; Toms, AV; Walker, D; Wang, Z; Yao, L	1
Bagal, SK; Bickerton, S; Bodnarchuk, MS; Breed, J; Carbajo, RJ; Cassar, DJ; Chakraborty, A; Cosulich, S; Cumming, I; Davies, M; Eatherton, A; Evans, L; Feron, L; Fillery, S; Gleave, ES; Goldberg, FW; Hanson, L; Harlfinger, S; Howard, M; Howells, R; Jackson, A; Kemmitt, P; Kettle, JG; Kingston, JK; Lamont, S; Lewis, HJ; Li, S; Liu, L; Ogg, D; Phillips, C; Polanski, R; Robb, G; Robinson, D; Ross, S; Smith, JM; Tonge, M; Whiteley, R; Yang, J; Zhang, L; Zhao, X	1
Chen, J; Cheng, Z; Fletcher, M; Jensen, BC; Liu, Y; Xia, P	1
Momo, K; Nio, Y; Sasaki, T; Shimizu, H; Sugita, H	1
Chin, HG; Fitzgerald, K; George, K; Hansen, U; Pedamallu, CS; Roberto, MP; Schaus, SE; Shah, J; Shin, H; Stoiber, P; Willoughby, JLS	1
Asou, H; Doi, T; Funai, T; Inoue, K; Kondo, S; Ranka, VK; Tajimi, M; Wacheck, V	1
Ben Taleb, A; Gözüaçık, D; Ilgar, M; Karakuş, S; Kilislioğlu, A; Kutlu, HM; Kutlu, Ö; Tan, E	1
Ahirrao, P; Bakhle, D; Bernstein, PR; Bhat, T; Bhonde, M; Bommakanti, A; Bora, P; Francis, A; George, KS; Gole, G; Goyal, H; Gundu, J; Gupta, NR; Gupta, R; Hajare, AK; Jadhav, GR; Jagdale, AR; Jana, G; Kale, R; Kamalakannan, P; Kamble, N; Kamboj, RK; Karche, NP; Khanwalkar, H; Khedkar, N; Kukreja, G; Kumar, P; Kumar, R; Kurhade, SP; Limaye, R; Mallurwar, S; Modi, D; Naidu, S; Naik, KR; Narasimham, L; Nemmani, K; Nigade, PB; Pagdala, V; Palle, VP; Patil, V; Pawar, S; Pawar, Y; Phukan, S; Powar, RG; Praveen Kumar, VR; Rao Irlapati, N; Shaikh, JS; Shankar, RB; Sharma, S; Singh, M; Sinha, N; Thube, BR; Tilekar, AR; Volam, H; Wahid, S	1
Chen, Y; Du, T; Han, J; Li, D; Li, G; Li, Z; Liu, M; Liu, Z; Wang, Q; Zhang, N	1
Bardaweel, SK; Hajjo, R; Haroon, RA; Sabbah, DA; Sweidan, K	1
Das, R; Mehta, DK; Sahu, RK; Sharma, D; Sharma, V	1
Anderson, B; Azaro, A; Benhadji, KA; Cassier, PA; Italiano, A; Massard, C; Merchan, J; Oakley, G; Pant, S; Tap, WD; Yu, D; Yuen, E	1
Merkus, D; Schermuly, RT	1
Bagrel, D; Botta, B; Czepukojc, B; Evain-Bana, E; Jacob, C; Kirsch, G; Mai, A; Meiser, P; Montenarh, M; Mori, M; Patsilinakos, A; Ragno, R; Stazi, G; Valente, S; Xu, Z; Zwergel, C	1
Kukowska, M	1
Callies, S; LaBell, ES; Lee, LB; Satonin, DK; Schmalz, CA; Wickremsinhe, ER	1
Chen, S; Hong, X; Li, LP; Lu, X; Ma, FE; Ni, QL; Pan, YM; Peng, Y; Wu, YM; Yang, JM; Zhang, Y	1
Aboshanab, KMA; Ashour, MS; El-Mahallawy, HA; Elkhatib, WF; Hamed, SM; Helmy, MM	1
Adjei, A; Allred, J; Goetz, M; Jazieh, K; Kaufmann, SH; Lim, VS; Molina, J; Reid, J; Yin, J	1
Chu, XM; Gong, KK; Liang, LL; Liu, W; Sun, KL; Wang, C; Zhao, CY	1
Ashton, TM; Herbert, KJ; Higgins, GS; Pirovano, G; Prevo, R	1
Adjei, AA; Boland, P; Brady, W; Dy, GK; Fetterly, G; Iyer, R; LeVea, C; Ma, WW; Mantione, K; Pitzonka, L; Schihl, S; Straubinger, RM; Tan, W; Whitworth, A; Wilton, J; Xie, H	1
Gao, F; Wang, T; Xiao, J; Zhang, X	1
Chen, D; Murugesan, S; Nadkarni, DH; Qin, JJ; Velu, SE; Wang, H; Wang, MH; Wang, W; Zhang, R	1
Gao, HY; Guan, Y; Jiang, Y; Shi, SP; Tu, PF; Wang, XX; Wu, LJ; Xiao, CL; Zan, K; Zeng, KW	1
Fox, JL	1
Fernandes, PA; Moorthy, NS; Ramos, MJ; Sousa, SF	1
Dalgleish, A; Damber, JE; Pili, R; Raymond, E; Smith, M	1
Aleksić, M; Bertoša, B; David-Cordonnier, MH; Depauw, S; Karminski-Zamola, G; Kralj, M; Martin-Kleiner, I; Nhili, R; Tomić, S	1
Hsu, TC; Wu, X; Zheng, YL	1
Galsky, MD; Gimpel-Tetra, K; Godbold, J; Holcombe, RF; Lee, KM; Lowe, N; Misiukiewicz, K; Oh, WK; Posner, M; Soto, R; Tsao, CK	1
Arterburn, JB; Hathaway, HJ; Nayak, TK; Norenberg, JP; Prossnitz, ER; Ramesh, C	1
Britten, CD; George, D; Kulkarni, S; Liu, A; Mortimer, J; Quinlan, M; Scott, JW; Sharma, S	1
Atalay, R; Banoglu, E; Çalışkan, B; Cankara Pirol, Ş; Durmaz, I	1
Chen, BJ; Tanaka, Y; Wu, YL; Zhang, W	1
Abécassis, PY; Angouillant-Boniface, O; Bertrand, T; Bjergarde, K; Carry, JC; Clerc, F; Combeau, C; Crocq-Stuerga, V; Delarbre, L; Delorme, C; Doerflinger, G; Filoche-Rommé, B; Gasse, F; Gontier, S; Guizani, H; Krick, A; Lachaud, S; Le Moigne, R; Lebel, R; Ma, N; Maignan, S; Mauger, J; Minoux, H; Monget, S; Monteiro, ML; Murer, M; Nair, A; Nicolas, JP; Parmantier, E; Perron, S; Pouzieux, S; Prévost, C; Schio, L	1
Carta, D; Ferlin, MG	1
Giglione, P; Liguigli, W; Paglino, C; Porta, C	1
George, D; Infante, JR; Liu, A; Quinlan, M; Ramanathan, RK; Scott, JW; Sharma, S; Tan, E	1
Hu, GQ; Liu, YH; Wang, TX; Wei, XL	1
Gadepalli Narasimha, KK; Gopalakrishnan, A; Kalpattu Kuppusami, B; Manogaran, P; Mariyappan, P; Raghavan, S; Venkatraman, G	1
Bisacchi, GS; Hale, MR	1
Check Hayden, E	1
Batalha, PN; Cruz, DC; da Costa Santos Boechat, F; Peña-Cabrera, E; Vieira de Souza, MC	1
Benites, J; Buc Calderon, P; Delgado, V; Muccioli, GG; Sepúlveda, S; Theoduloz, C; Valderrama, JA	1
Becerra, C; Bruce, J; Carlson, G; Chung, V; Goel, S; Infante, J; Kabbinavar, F; Lockhart, AC; Munster, P; Pant, S; Patel, MR; Sarantopoulos, J; Scott, JW; Sharma, S; Tan, E; Tawbi, H; Yang, S	1
Bantu, R; Banu, S; Bollu, R; Jain, N; Manga, V; Nagarapu, L; Polepalli, S; Vangala, R	1
Alfonsi, R; Botta, B; Cacchi, S; Di Marcotullio, L; Fabrizi, G; Faedda, R; Goggiamani, A; Iazzetti, A; Mori, M	1
Cho, SH; James, TD; Jang, JH; Kang, C; Kim, JS; Kim, WR; Sharma, A	1
Algara, T; Aparicio, S; Balasubramanian, S; Bally, MB; Banáth, J; Brenton, JD; Brown, GW; Caldas, C; Cescon, D; Chiu, DS; Di Antonio, M; Garcia, J; Hieter, P; Ho, B; Kabeer, F; Lai, D; Le, DD; Lin, SC; Mak, TW; Mathew, V; McKinney, S; O'Neil, NJ; Osako, T; Santos, ND; Saunders, DN; Shah, SP; Silvester, J; Soong, J; Soriano, P; Stirling, PC; Thu, K; Tsai, AH; Wei, V; Wong, J; Xian, J; Xu, H; Yap, D; Ye, FB; Zhang, A	1
Cheng, L; Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC	1
Chen, XG; Chern, JW; Guo, QL; He, XG; Huang, CH; Li, TK; Li, ZY; Wang, XJ; Yang, Q; You, QD	1
Anderes, K; Bliesath, J; Drygin, D; Ho, CB; Lim, JK; Lin, A; O'Brien, S; Proffitt, C; Rice, WG; Schwaebe, M; Siddiqui-Jain, A; Trent, K; Von Hoff, D; Whitten, JP	1
Blaskovich, MA; El Naggar, AK; Gagel, RF; Hong, DS; Khan, R; Kurzrock, R; Moulder, S; Naing, A; Newman, RA; Ng, CS; Sebti, SM; Sherman, SI; Tannir, NM; Trent, J; Wheler, JJ; Wright, JJ; Ye, L	1
Adelman, DC; Advani, RH; Allen, RS; Berman, CJ; Ebbinghaus, SW; Fox, JA; Gordon, MS; Havrilla, NA; Hoch, U; Hurwitz, HI; Mendelson, DS; Silverman, JA; Wakelee, HA	1
Gray, NS; Hur, W; Jiang, T; Luesch, H; Mason, DE; Peters, EC; Schultz, PG; Sun, Z; Zhang, DD	1
Ezell, SJ; Gurpinar, E; Li, H; Rayburn, ER; Sommers, CI; Velu, SE; Wang, W; Xu, H; Yang, X; Zhang, R; Zhang, X	1
Chandhasin, C; Kurzrock, R; Tsimberidou, AM	1
Calderon, PB; Valderrama, JA; Vásquez, DR; Verrax, J	1
Boettger, S; Breitbart, W	1
Fukuhara, K; Hayaishi, Y; Katsuragi, K; Kodama, S; Morisya, Y; Nakanishi, C; Terakura, M	1
Fraser, A; Gafter-Gvili, A; Kremer, LC; Lawrie, TA; Leibovici, L; Paul, M; van de Wetering, MD; Vidal, L	1
Huang, X; Li, W; Yang, XW	1
de Souza, MV; Facchinetti, V; Gomes, CR; Vasconcelos, TR	1
Kondratyuk, TP; Luqman, S; Marler, LE; Meena, A; Negi, AS; Pezzuto, JM; Singh, P	1
Anand, S; Beijnen, JH; Dubbelman, AC; Krone, K; Marchetti, S; Schellens, JH; Tan, E; Upthagrove, A	1
Antony, L; Björk, A; Björk, P; Brennen, WN; Dalrymple, SL; Gerber, S; Hammers, H; Isaacs, JT; Kachhap, S; Leanderson, T; Luo, J; Olsson, A; Wissing, M; Xing, L	1
Horton, JK; Wilson, SH	1
Anak, O; Angevin, E; Dugan, M; Escudier, B; Feng, Y; Kay, A; Schran, H; Wang, X; Zhou, W	1
Cheson, BD; Gravell, AE; Wright, JJ; Zerivitz, K	1
Adjei, AA; Dy, GK; Haluska, P	1
Bonginelli, P; Capaccetti, B; Fanelli, M; Gasparini, G; Gattuso, D; Longo, R; Sarmiento, R	1
De la Fuente, JA; Eguiraun, A; Gutierrez, P; León, J; Lorenzo, M; Montero, JC; Ortiz, JM; Pandiella, A; Pipaón, C	1
Jia, G; Lown, JW; Sharma, SK	1
Nishiyama, M; Tahara, E; Tsuruo, T; Yasui, W	1
Angibaud, P; End, D; Venet, M	1
Adjei, AA; Alberts, SR; Atherton, P; Bruzek, LM; Croghan, GA; Erlichman, C; Goldberg, RM; Hanson, LJ; Kaufmann, SH; Marks, RS; Palmer, PA; Pitot, HC; Reid, JM; Sloan, JA; Thibault, A	1
Eckhardt, SG; Gentner, L; Goetz, A; Hammond, LA; Izbicka, E; McCreery, H; Mori, M; Patnaik, A; Richards, H; Rowinsky, EK; Rybak, ME; Schwartz, G; Takimoto, CH; Terada, K; Tolcher, AA; Zhang, S	1
Alpaugh, RK; Cohen, SJ; Gallo, J; Gentner, L; Lewis, NL; Meropol, NJ; Palmer, PA; Rogatko, A; Schol, J; Verhaeghe, T; Weiner, LM; Yeslow, G; Zannikos, P	1
de Bruijn, P; de Heus, G; de Jonge, MJ; Eskens, FA; Kehrer, DF; Klaren, A; Mathijssen, RH; Palmer, PA; Planting, AS; Sparreboom, A; Verhaeghe, T; Verheij, C; Verweij, J; Xie, R; Zhang, S	1
Marsh, S; Mathijssen, RH; McLeod, HL; Sparreboom, A; Verweij, J	1
Frisbee-Hume, S; LeBlanc, B; Rolston, KV; Streeter, H; Vaziri, I	1
Bartkowski, LM; Ferrante, KJ; Kajiji, SM; Langevin, M; Lush, R; Mahany, JJ; Moulder, SL; Noe, DA; Paillet, S; Rocha-Lima, C; Sullivan, DM	1
Doroshow, JH; Frankel, P; Gandara, DR; Gumerlock, PH; Kawaguchi, T; Lara, PN; Lau, DH; Law, LY; Lenz, HJ; Twardowski, P; Wright, JJ	1
Helbig, G; Hołowiecki, J	1
Abbruzzese, A; Budillon, A; Caponigro, F; Caraglia, M; Marra, M; Tagliaferri, P	1
Kurzrock, R	1
Fraser, A; Gafter-Gvili, A; Kremer, L; Leibovici, L; Paul, M; van de Wetering, M	1
Beijnen, JH; Crul, M; Howes, A; Pluim, D; Schellens, JH; Siegel-Lakhai, WS; Solanki, B; Sparidans, RW; Zhang, S	1
Almyroudis, NG; Segal, BH	1
Boutros, R; Dozier, C; Ducommun, B	1
Mesa, RA	1
Favaudon, V; Fernet, M; Giocanti, N; Godon, C; Mégnin-Chanet, F; Noël, G	1
Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN	1
De Porre, P; Hayes, S; Perez-Ruixo, JJ; Piotrovskij, V; Zannikos, P; Zhang, S	1
Cohen, RB; Eckhardt, SG; Gore, L; Gustafson, D; Holden, SN; Mikule, C; Morrow, M; O'Bryant, CL; Palmer, PA; Persky, M; Pierson, AS; Zhang, S	1
Awada, A; De Porre, P; Dirix, LY; Francois, M; Fumoleau, P; Piccart-Gebhart, M; Verhaeghe, T; Zannikos, P; Zhang, S	1
Beijnen, JH; Boot, H; Chang, I; Crul, M; De Porre, P; Schellens, JH; Siegel-Lakhai, WS; Zhang, S	1
Chen, YC; Guh, JH; Ho, YF; Huang, YC; Kuo, SC; Lin, TP; Lu, PH; Pan, SL; Teng, CM	1
Awada, A; De Porre, P; de Valeriola, D; Gil, T; Lalami, Y; Piccart-Gebhart, MJ; Zhang, S	1
Abbruzzese, A; Arra, C; Baldi, A; Barbieri, A; Budillon, A; Caraglia, M; D'Alessandro, AM; Marra, M; Meo, G; Rapp, UR; Tagliaferri, P; Tassone, P; Venuta, S; Viscomi, C	1
Fraser, A; Gafter-Gvili, A; Leibovici, L; Paul, M	1
Chide, OE; Orisakwe, OE	1
Aziz, N; Braendle, E; Butzberger-Zimmerli, P; de Bono, JS; Evans, TR; Fox, JA; Garzon, F; Hardie, M; Heise, C; Jadayel, D; Judson, IR; Louie, S; Marriott, C; Michelson, G; Molife, R; Morrison, R; Sarker, D	1
Decker, EA	1
Alder, J; Burres, N; Chu, DT; Clement, JJ; Jarvis, K; Swiniarski, J	1
Aoun, M; Bourguignon, AM; Daneau, D; Janssen, M; Meunier, F; Van der Auwera, P; Varthalitis, I	1
Brunet, S; Domingo-Albós, A; Martínez, C; Martino, R; Pericas, R; Salazar, R; Solá, C; Sureda, A	1
D'Antonio, D; Di Marzio, A; Fioritoni, G; Lacone, A; Lombardo, M; Pizzigallo, E; Romano, F; Staniscia, T; Violante, B	1
Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H	1
Drlica, K; Zhao, X	1
Barza, M; Engels, EA; Lau, J	1
Blatner, GL; Cheson, BD; Wright, J	1
Belly, RT; Bol, CJ; Bowden, C; Chiao, J; Chow, C; Cowan, KH; End, DW; Gress, RE; Hakim, FT; Horak, ID; Kohler, DR; Kopp, WC; Kremer, AB; Larkin, G; Noone, M; Nussenblatt, RB; Piotrovsky, VK; Todd, A; Woestenborghs, R; Zujewski, J	1
Bol, CJ; Punt, CJ; Seifert, WF; van Maanen, L; Wagener, DJ	1
Gabrilove, JL	1
Adjei, AA; End, DW; Karp, JE; Kaufmann, SH; Lancet, JE; Wright, JJ	1
Norman, P	1
Beijnen, JH; Boerrigter, L; Bol, CJ; Crul, M; de Gast, GC; de Jong, D; de Klerk, GJ; Palmer, PA; Schellens, JH; Swart, M; Tan, H; van't Veer, LJ	1
Bodey, GP; Ho, DH; LeBlanc, B; Rolston, KV	1
Bodey, GP; Gooch, G; Ho, DH; LeBlanc, B; Rolston, KV	2

Reviews

34 review(s) available for carbostyril and Neoplasms

Article	Year
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide	2023
Exploring Quinolone Scaffold: Unravelling the Chemistry of Anticancer Drug Design. Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:1 Topics: Antineoplastic Agents; Drug Design; Humans; Neoplasms; Quinolones; Structure-Activity Relationship	2022
Amino acid or peptide conjugates of acridine/acridone and quinoline/quinolone-containing drugs. A critical examination of their clinical effectiveness within a twenty-year timeframe in antitumor chemotherapy and treatment of infectious diseases. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Nov-15, Volume: 109 Topics: Acridines; Acridones; Amino Acids; Animals; Anti-Infective Agents; Antineoplastic Agents; Communicable Diseases; Humans; Neoplasms; Peptides; Quinolines; Quinolones; Treatment Outcome	2017
Quinoline and quinolone dimers and their biological activities: An overview. European journal of medicinal chemistry, 2019, Jan-01, Volume: 161 Topics: Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Bacteria; Dimerization; Humans; Neoplasms; Quinolines; Quinolones	2019
T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics. Cell death & disease, 2018, 10-24, Volume: 9, Issue:11 Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Drug Discovery; Humans; Indolizines; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Neoplasms; Quinolones; Quinoxalines; Thiophenes; Treatment Outcome	2018
Quinolone hybrids and their anti-cancer activities: An overview. European journal of medicinal chemistry, 2019, Mar-01, Volume: 165 Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship	2019
Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis. Current medicinal chemistry, 2013, Volume: 20, Issue:38 Topics: Antineoplastic Agents; Biological Products; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Piperidines; Pyridines; Quantitative Structure-Activity Relationship; Quinolones	2013
Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Immune System; Neoplasms; Quinolines; Quinolones; Tumor Microenvironment	2014
Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. International journal of biological sciences, 2014, Volume: 10, Issue:10 Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzoxazines; Cell Transformation, Neoplastic; Dimerization; Drug Discovery; G-Quadruplexes; Gene Components; Gene Expression Regulation, Neoplastic; Humans; Indoles; Ligands; Molecular Structure; Neoplasms; Perylene; Proto-Oncogene Proteins c-myc; Quinolines; Quinolones; Ribosomes	2014
An overview on 2-arylquinolin-4(1H)-ones and related structures as tubulin polymerisation inhibitors. Current topics in medicinal chemistry, 2014, Volume: 14, Issue:20 Topics: Antineoplastic Agents; Cell Line, Tumor; Colchicine; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Microtubules; Mitosis; Naphthyridines; Neoplasms; Quinazolinones; Quinolones; Signal Transduction; Structure-Activity Relationship; Tubulin Modulators	2014
A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone. Current medicinal chemistry, 2016, Volume: 23, Issue:6 Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; DNA Topoisomerases, Type II; Drug Discovery; Humans; Models, Molecular; Neoplasms; Quinolones; Signal Transduction; Topoisomerase II Inhibitors	2016
Quinolones in the Search for New Anticancer Agents. Current pharmaceutical design, 2016, Volume: 22, Issue:39 Topics: Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Quinolones	2016
Farnesyltransferase inhibitors: where are we now? Expert opinion on investigational drugs, 2010, Volume: 19, Issue:12 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Neoplasms; Quinolones	2010
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. The Cochrane database of systematic reviews, 2012, Jan-18, Volume: 1 Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Cause of Death; Drug Resistance, Bacterial; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Neoplasms; Neutropenia; Quinolones; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination	2012
Perspectives on the development of novel potentially active quinolones against tuberculosis and cancer. Mini reviews in medicinal chemistry, 2012, Volume: 12, Issue:9 Topics: Animals; Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Survival; Drug Design; Drug Discovery; Humans; Mice; Microbial Viability; Mycobacterium tuberculosis; Neoplasms; Quinolones; Structure-Activity Relationship; Tuberculosis, Pulmonary	2012
Farnesyl transferase inhibitors as anticancer agents. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:13 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Imidazoles; Neoplasms; Piperidines; Pyridines; Quinolones; Tumor Cells, Cultured	2002
[Innovative treatment in oncology]. Recenti progressi in medicina, 2002, Volume: 93, Issue:11 Topics: Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinolones	2002
Novel cyclopropylindole conjugates and dimers: synthesis and anti-cancer evaluation. Current medicinal chemistry. Anti-cancer agents, 2001, Volume: 1, Issue:1 Topics: Animals; Cyclopropanes; Dimerization; Drug Evaluation; Humans; Indolequinones; Indoles; Neoplasms; Quinolones	2001
Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery. Current topics in medicinal chemistry, 2003, Volume: 3, Issue:10 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Mice; Molecular Structure; Neoplasms; Protein Prenylation; Quinolones; Structure-Activity Relationship	2003
[Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2004, Volume: 57, Issue:9-10 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Farnesyltranstransferase; Genes, ras; GTP-Binding Proteins; Guanosine Triphosphate; Humans; Imidazoles; Neoplasms; Piperidines; Point Mutation; Pyridines; Quinolones; Signal Transduction	2004
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Current drug targets, 2005, Volume: 6, Issue:3 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzodiazepines; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mevalonic Acid; Neoplasms; Phosphatidylinositol 3-Kinases; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; ras Proteins	2005
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. The Cochrane database of systematic reviews, 2005, Oct-19, Issue:4 Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Neoplasms; Neutropenia; Quinolones; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination	2005
The when and wheres of CDC25 phosphatases. Current opinion in cell biology, 2006, Volume: 18, Issue:2 Topics: Animals; Benzoquinones; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Humans; Isoenzymes; Models, Biological; Naphthoquinones; Neoplasms; Quinolones; Quinones; Thiazoles	2006
Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert review of anticancer therapy, 2006, Volume: 6, Issue:3 Topics: Clinical Trials as Topic; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Treatment Outcome	2006
[Problems in the current target therapy of malignancies]. Voprosy onkologii, 2005, Volume: 51, Issue:5 Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab	2005
Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. British journal of clinical pharmacology, 2006, Volume: 62, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Capsules; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Quinolones; Tablets	2006
The anti-cancer effects of quinolone antibiotics? European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2007, Volume: 26, Issue:11 Topics: Antibiotics, Antineoplastic; Humans; Neoplasms; Quinolones	2007
Structural development, haematological immunological and pharmacological effects of quinolones. Recent patents on anti-infective drug discovery, 2007, Volume: 2, Issue:2 Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Blood Cell Count; Blood Cells; Chemotaxis, Leukocyte; Cytokines; Drug Resistance, Bacterial; Humans; Immunologic Factors; Lipopolysaccharides; Neoplasms; Neutropenia; Patents as Topic; Quinolones; Sepsis; Structure-Activity Relationship	2007
The role of phenolics, conjugated linoleic acid, carnosine, and pyrroloquinoline quinone as nonessential dietary antioxidants. Nutrition reviews, 1995, Volume: 53, Issue:3 Topics: Animals; Antioxidants; Arteriosclerosis; Carnosine; Diet; Humans; Linoleic Acid; Linoleic Acids; Neoplasms; Phenols; PQQ Cofactor; Quinolones	1995
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and molecular biology reviews : MMBR, 1997, Volume: 61, Issue:3 Topics: Bacteria; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Bacterial; Drug Resistance, Microbial; Genes, Bacterial; Neoplasms; Quinolones	1997
Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:3 Topics: Anti-Infective Agents; Antineoplastic Agents; Fever; Humans; Neoplasms; Neutropenia; Opportunistic Infections; Quinolones; Randomized Controlled Trials as Topic; Risk; Trimethoprim, Sulfamethoxazole Drug Combination	1998
Cancer therapy. New strategies and treatment modalities for optimizing patient outcomes. Seminars in hematology, 2001, Volume: 38, Issue:3 Suppl 7 Topics: Alkyl and Aryl Transferases; Anemia; Enzyme Inhibitors; Erythropoietin; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Recombinant Proteins	2001
Current status of clinical trials of farnesyltransferase inhibitors. Current opinion in oncology, 2001, Volume: 13, Issue:6 Topics: Alkyl and Aryl Transferases; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Leukemia; Neoplasms; Piperidines; Pyridines; Quinolones; Signal Transduction	2001
Tipifarnib (Janssen Pharmaceutica). Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:2 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Ataxia; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drugs, Investigational; Farnesyltranstransferase; Humans; Neoplasms; Quinolones; Structure-Activity Relationship; Thrombocytopenia; Treatment Outcome	2002

Trials

32 trial(s) available for carbostyril and Neoplasms

Article	Year
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide	2023
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. Investigational new drugs, 2020, Volume: 38, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinolones; Response Evaluation Criteria in Solid Tumors; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases	2020
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Investigational new drugs, 2021, Volume: 39, Issue:4 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Benzimidazoles; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Pyridines; Quinolones	2021
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Investigational new drugs, 2019, Volume: 37, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinolones; Salvage Therapy; Tissue Distribution	2019
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. American journal of clinical oncology, 2019, Volume: 42, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Prognosis; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Tissue Distribution	2019
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Quinolones; Thromboembolism; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult	2014
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4 Topics: Administration, Oral; Aged; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Biological Availability; Capsules; Cross-Over Studies; Dietary Fats; Female; Food Analysis; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Quinolones; Therapeutic Equivalency; Treatment Outcome	2014
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Biological Availability; Capsules; Cross-Over Studies; Disease-Free Survival; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinolones; Tablets	2015
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Capsules; Cross-Over Studies; Demography; Drug Compounding; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinolones; Tablets; Therapeutic Equivalency; Treatment Outcome; Young Adult	2016
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Nov-15, Volume: 15, Issue:22 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Treatment Outcome	2009
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Apr-01, Volume: 16, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Naphthyridines; Neoplasms; Quinolones; Recurrence; Thiazoles; Treatment Outcome; Young Adult	2010
An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. Palliative & supportive care, 2011, Volume: 9, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delirium; Female; Humans; Inpatients; Male; Middle Aged; Neoplasms; Piperazines; Prospective Studies; Quinolones; Severity of Illness Index; Statistics, Nonparametric	2011
Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:5 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzimidazoles; Chromatography, Liquid; Cohort Studies; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinolones; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tandem Mass Spectrometry; Tissue Distribution; Young Adult	2012
Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib. Journal of clinical pharmacology, 2013, Volume: 53, Issue:1 Topics: Benzimidazoles; Drug Administration Schedule; Female; Humans; Male; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Quinolones; Vascular Endothelial Growth Factor A	2013
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Electrolytes; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Quinolones; Time Factors	2003
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Models, Chemical; Neoplasms; Protein Prenylation; Quinolones; ras Proteins; Time Factors; Treatment Outcome	2003
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:6 Topics: Administration, Oral; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Quinolones	2004
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor. British journal of cancer, 2004, Apr-19, Volume: 90, Issue:8 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Treatment Outcome	2004
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Humans; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Quinolones; Tandem Repeat Sequences	2004
A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-01, Volume: 10, Issue:21 Topics: Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Area Under Curve; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Imidazoles; Inhibitory Concentration 50; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Quinolones; Time Factors	2004
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anti-cancer drugs, 2005, Volume: 16, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; California; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Protein Prenylation; Quinolones	2005
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. British journal of cancer, 2005, Nov-28, Volume: 93, Issue:11 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones	2005
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:11 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Prenylation; Quinolones	2006
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer. Journal of clinical pharmacology, 2006, Volume: 46, Issue:10 Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Female; Glucuronides; Glycoproteins; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Binding; Quinolones; Serum Albumin; Tablets; Treatment Outcome	2006
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28 Topics: Adult; Aged; Area Under Curve; Farnesyltranstransferase; Female; Humans; Liver; Male; Middle Aged; Models, Statistical; Neoplasms; Neutrophils; Quinolones; Time Factors	2006
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies. Current medical research and opinion, 2007, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Female; Humans; Immune System; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Taxoids; Treatment Outcome	2007
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Apr-01, Volume: 14, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzimidazoles; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolones; Treatment Outcome	2008
A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1994, Volume: 2, Issue:3 Topics: 4-Quinolones; Adult; Aged; Anti-Infective Agents; Bacteremia; Drug Resistance, Microbial; Drug Tolerance; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Neoplasms; Pefloxacin; Pneumonia; Prospective Studies; Quinolones; Staphylococcal Infections; Teicoplanin	1994
The impact of rufloxacin given as prophylaxis to patients with cancer on their oral and faecal microflora. The Journal of antimicrobial chemotherapy, 1996, Volume: 38, Issue:5 Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteroides; Colony Count, Microbial; Drug Resistance, Microbial; Enterobacteriaceae; Feces; Female; Fluoroquinolones; Humans; Male; Middle Aged; Mouth; Neoplasms; Pilot Projects; Quinolones; Staphylococcus; Streptococcus	1996
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4 Topics: Administration, Oral; Adult; Aged; Alkyl and Aryl Transferases; Anemia; Biological Availability; Bone Marrow; Capsules; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Half-Life; Headache; Humans; Hypotension; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Peripheral Nervous System Diseases; Quinolones; Solutions; Vomiting	2000
Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anti-cancer drugs, 2001, Volume: 12, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Biological Availability; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Quinolones; Time Factors; Vomiting	2001
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-01, Volume: 20, Issue:11 Topics: Administration, Oral; Alkyl and Aryl Transferases; Antineoplastic Agents; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Genes, ras; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Nausea; Neoplasms; Quinolones; Vomiting	2002

Other Studies

65 other study(ies) available for carbostyril and Neoplasms

Article	Year
Discovery, synthesis and molecular substantiation of N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides as anticancer agents. Bioorganic chemistry, 2019, Volume: 91 Topics: Alkaline Phosphatase; Antineoplastic Agents; Cell Proliferation; Drug Discovery; High-Throughput Screening Assays; Humans; Hydroxyquinolines; Molecular Structure; Neoplasms; Quinolines; Signal Transduction; Structure-Activity Relationship; Tumor Cells, Cultured	2019
Elucidation of structure-activity relationship of 2-quinolone derivatives and exploration of their antitumor potential through Bax-induced apoptotic pathway. Chemical biology & drug design, 2012, Volume: 80, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxyquinolines; Mice; Neoplasms; Quinolones	2012
PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study. Molecular cancer, 2022, 02-08, Volume: 21, Issue:1 Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Quinolones	2022
Exploration of quinolone and quinoline derivatives as potential anticancer agents. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2019, Volume: 27, Issue:2 Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Drug Screening Assays, Antitumor; HeLa Cells; Humans; K562 Cells; MCF-7 Cells; Neoplasms; Quinolines; Quinolones	2019
4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin. European journal of medicinal chemistry, 2019, Nov-01, Volume: 181 Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Cell Proliferation; Colchicine; Drug Resistance, Neoplasm; Humans; Molecular Docking Simulation; Neoplasms; Quinolones; Tubulin; Tubulin Modulators	2019
CRISPR reveals some cancer drugs hit unexpected targets. Science (New York, N.Y.), 2019, 09-13, Volume: 365, Issue:6458 Topics: Antineoplastic Agents; CRISPR-Cas Systems; Cyclin-Dependent Kinases; Drug Development; Gene Silencing; Humans; Molecular Targeted Therapy; Neoplasms; Quinolones	2019
Dihydroquinoline derivative as a potential anticancer agent: synthesis, crystal structure, and molecular modeling studies. Molecular diversity, 2021, Volume: 25, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; Mice; Models, Molecular; Molecular Docking Simulation; Neoplasms; Quinolines; Quinolones; Structure-Activity Relationship; Vero Cells	2021
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor. Journal of medicinal chemistry, 2020, 02-27, Volume: 63, Issue:4 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Isocitrate Dehydrogenase; Mice, Inbred BALB C; Molecular Structure; Neoplasms; Protein Binding; Pyridines; Quinolines; Quinolones; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2020
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS Journal of medicinal chemistry, 2020, 05-14, Volume: 63, Issue:9 Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Drug Design; Humans; Male; Mice, Nude; Molecular Conformation; Mutation; Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinolones; Rats, Wistar; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2020
Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1. The Journal of biological chemistry, 2020, 03-27, Volume: 295, Issue:13 Topics: Animals; Apoptosis; Atrophy; Cardiotoxicity; Cyclin-Dependent Kinase 2; Disease Models, Animal; Doxorubicin; Forkhead Box Protein O1; Gene Expression Regulation; Heart; Humans; Mice; Muscle Proteins; Myocytes, Cardiac; Neoplasms; Quinolones; Signal Transduction; Tripartite Motif Proteins; Ubiquitin-Protein Ligases	2020
Prophylactic Quinolone Prescription Patterns Related to Febrile Neutropenia in Cancer Chemotherapy Outpatients. Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:3 Topics: Febrile Neutropenia; Humans; Neoplasms; Outpatients; Quinolones; Retrospective Studies	2020
Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence. BMC cancer, 2020, Jun-15, Volume: 20, Issue:1 Topics: Apoptosis; Benzodioxoles; Cell Cycle Checkpoints; Cell Division; Cellular Senescence; Chromosomes, Human; DNA-Binding Proteins; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Intravital Microscopy; Molecular Targeted Therapy; Neoplasms; Quinolones; RNA, Small Interfering; Time-Lapse Imaging; Transcription Factors	2020
Antitumor Efficacy of Ceranib-2 with Nano-Formulation of PEG and Rosin Esters. Methods in molecular biology (Clifton, N.J.), 2021, Volume: 2207 Topics: Antineoplastic Agents; Drug Carriers; HeLa Cells; Humans; Neoplasms; Polyethylene Glycols; Quinolones; Resins, Plant	2021
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization. Bioorganic & medicinal chemistry, 2020, 12-15, Volume: 28, Issue:24 Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Survival; Half-Life; Humans; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Naphthyridines; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinolones; Structure-Activity Relationship; Transplantation, Heterologous	2020
Design, synthesis and biological evaluation of dihydro-2-quinolone platinum(iv) hybrids as antitumor agents displaying mitochondria injury and DNA damage mechanism. Dalton transactions (Cambridge, England : 2003), 2021, Jan-07, Volume: 50, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Line; DNA; DNA Damage; Histones; Humans; Male; Mice, Inbred BALB C; Mitochondria; Neoplasms; Organoplatinum Compounds; Quinolones; Reactive Oxygen Species; Serum Albumin; Tumor Suppressor Protein p53	2021
Molecules (Basel, Switzerland), 2020, Dec-25, Volume: 26, Issue:1 Topics: Amides; Caco-2 Cells; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Molecular Docking Simulation; Neoplasms; Quinolones; Transcription Factors	2020
Farnesylation of RhoB: the cancer hypothesis of pulmonary hypertension revisited. Cardiovascular research, 2017, 03-01, Volume: 113, Issue:3 Topics: Humans; Hypertension, Pulmonary; Hypoxia; Neoplasms; Prenylation; Quinolones; rhoB GTP-Binding Protein	2017
Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. European journal of medicinal chemistry, 2017, Jul-07, Volume: 134 Topics: Antineoplastic Agents; Apoptosis; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coumarins; Enzyme Inhibitors; Humans; Neoplasms; Quantitative Structure-Activity Relationship; Quinolones	2017
Incorporating dried blood spot LC-MS/MS analysis for clinical development of a novel oncolytic agent. Bioanalysis, 2018, Mar-01, Volume: 10, Issue:5 Topics: Administration, Oral; Antineoplastic Agents; Calibration; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Data Accuracy; Dried Blood Spot Testing; Hematocrit; Humans; Neoplasms; Pyridines; Quinolones; Sensitivity and Specificity; Tandem Mass Spectrometry	2018
Preparation of Rhodium(III) complexes with 2(1H)-quinolinone derivatives and evaluation of their in vitro and in vivo antitumor activity. European journal of medicinal chemistry, 2018, May-10, Volume: 151 Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Coordination Complexes; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Mice; Models, Molecular; Neoplasms; Phosphorylation; Quinolones; Rhodium; Xenograft Model Antitumor Assays	2018
Plasmid-Mediated Quinolone Resistance in Gram-Negative Pathogens Isolated from Cancer Patients in Egypt. Microbial drug resistance (Larchmont, N.Y.), 2018, Volume: 24, Issue:9 Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Egypt; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Neoplasms; Plasmids; Quinolones	2018
Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ. Current cancer drug targets, 2013, Volume: 13, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line; Cell Proliferation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Mammary Glands, Human; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; MCF-7 Cells; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Stability; Pyrroles; Quinolones; Transforming Growth Factor beta2; Ubiquitination; Up-Regulation	2013
Quinolone alkaloids with antibacterial and cytotoxic activities from the fruits of Evodia rutaecarpa. Fitoterapia, 2013, Volume: 89 Topics: Alkaloids; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Bacteria; Evodia; Fruit; HeLa Cells; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Neoplasms; Phytotherapy; Plant Extracts; Quinolones	2013
FDA moves on breakthrough therapies. Nature biotechnology, 2013, Volume: 31, Issue:5 Topics: Aminophenols; Aminopyridines; Benzodioxoles; Drug Approval; Neoplasms; Quinolones; Terminal Care; United States	2013
Anilides and quinolones with nitrogen-bearing substituents from benzothiophene and thienothiophene series: synthesis, photochemical synthesis, cytostatic evaluation, 3D-derived QSAR analysis and DNA-binding properties. European journal of medicinal chemistry, 2014, Volume: 71 Topics: Anilides; Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; DNA; Drug Screening Assays, Antitumor; Humans; Neoplasms; Nitrogen; Quantitative Structure-Activity Relationship; Quinolones; Thiophenes; Topoisomerase II Inhibitors	2014
Mutagen sensitivity as measured by induced chromatid breakage as a marker of cancer risk. Methods in molecular biology (Clifton, N.J.), 2014, Volume: 1105 Topics: 4-Nitroquinoline-1-oxide; 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Bleomycin; Cells, Cultured; Chromatids; DNA Breaks, Double-Stranded; Genetic Markers; Genetic Predisposition to Disease; Humans; Lymphocytes; Mutagens; Neoplasms; Quinolones; Radiation Injuries; Risk	2014
GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding. Molecular cancer research : MCR, 2014, Volume: 12, Issue:11 Topics: Animals; Binding, Competitive; Cell Line, Tumor; Diagnostic Imaging; Estrogens; Female; Humans; Immunohistochemistry; Ligands; Mice, Nude; Neoplasms; Ovariectomy; Quinolones; Receptors, Estrogen; Staining and Labeling; Technetium; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays	2014
Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines. European journal of medicinal chemistry, 2014, Nov-24, Volume: 87 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carboxylic Acids; Cell Cycle Checkpoints; Cell Proliferation; Drug Screening Assays, Antitumor; Flow Cytometry; G1 Phase; Humans; Molecular Structure; Neoplasms; Pyrazoles; Quinolones; Structure-Activity Relationship; Tumor Cells, Cultured	2014
SAR156497, an exquisitely selective inhibitor of aurora kinases. Journal of medicinal chemistry, 2015, Jan-08, Volume: 58, Issue:1 Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Aurora Kinase C; Aurora Kinases; Benzimidazoles; Female; HCT116 Cells; Humans; Mice, SCID; Models, Chemical; Models, Molecular; Molecular Structure; Neoplasms; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinolones; Sf9 Cells; Small Molecule Libraries; Xenograft Model Antitumor Assays	2015
Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future oncology (London, England), 2015, Volume: 11, Issue:1 Topics: Benzimidazoles; Clinical Trials as Topic; Humans; Neoplasms; Quinolones; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2015
Quinolone-indolone conjugate induces apoptosis by inhibiting the EGFR-STAT3-HK2 pathway in human cancer cells. Molecular medicine reports, 2015, Volume: 12, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Hexokinase; Humans; Neoplasms; Quinolones; Signal Transduction; STAT3 Transcription Factor	2015
Synthesis and anticancer activity of novel curcumin-quinolone hybrids. Bioorganic & medicinal chemistry letters, 2015, Sep-01, Volume: 25, Issue:17 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Curcumin; Humans; Neoplasms; Quinolones; Reactive Oxygen Species	2015
Promising gene therapies pose million-dollar conundrum. Nature, 2016, 06-16, Volume: 534, Issue:7607 Topics: Aminophenols; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biotechnology; Cystic Fibrosis; Drug Costs; Drug Industry; Genetic Therapy; Humans; Insurance, Health; Neoplasms; Quinolones; Sofosbuvir	2016
Synthesis and Cytotoxic Activity on Human Cancer Cells of Novel Isoquinolinequinone-Amino Acid Derivatives. Molecules (Basel, Switzerland), 2016, Sep-08, Volume: 21, Issue:9 Topics: Amino Acids; Antineoplastic Agents; Cell Line, Tumor; Cytotoxins; Drug Screening Assays, Antitumor; Humans; Neoplasms; Quinolones	2016
Design, synthesis and docking studies of novel 1,2-dihydro-4-hydroxy-2-oxoquinoline-3-carboxamide derivatives as a potential anti-proliferative agents. European journal of medicinal chemistry, 2017, Jan-05, Volume: 125 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Molecular Docking Simulation; Neoplasms; Piperazines; Quinolones; Tubulin Modulators	2017
Design, Palladium-Catalyzed Synthesis, and Biological Investigation of 2-Substituted 3-Aroylquinolin-4(1H)-ones as Inhibitors of the Hedgehog Signaling Pathway. Journal of medicinal chemistry, 2017, 02-23, Volume: 60, Issue:4 Topics: Animals; Antineoplastic Agents; Catalysis; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Design; Hedgehog Proteins; Humans; Mice; Models, Molecular; Neoplasms; Palladium; Quinolones; Signal Transduction	2017
Targeted tumor detection: guidelines for developing biotinylated diagnostics. Chemical communications (Cambridge, England), 2017, Feb-09, Volume: 53, Issue:13 Topics: 1-Naphthylamine; Biotin; Biotinylation; Fluorescent Dyes; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Microscopy, Confocal; Microscopy, Fluorescence; Naphthalimides; Neoplasms; Optical Imaging; Quinolones	2017
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nature communications, 2017, 02-17, Volume: 8 Topics: Animals; Base Sequence; Benzothiazoles; Benzoxazines; BRCA1 Protein; BRCA2 Protein; Caenorhabditis elegans; Cell Line, Tumor; Chromosomal Instability; DNA Damage; DNA Repair; DNA Replication; DNA, Ribosomal; Female; G-Quadruplexes; Genome, Human; Genotype; Homologous Recombination; Humans; Mice; Naphthyridines; Neoplasms; Quinolones; Saccharomyces cerevisiae; Transcription, Genetic; Xenograft Model Antitumor Assays	2017
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31). Bioorganic & medicinal chemistry, 2008, Aug-15, Volume: 16, Issue:16 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays	2008
Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. Journal of medicinal chemistry, 2009, Sep-24, Volume: 52, Issue:18 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Drug Discovery; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Conformation; Naphthyridines; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Transplantation, Heterologous	2009
Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer research, 2009, Oct-01, Volume: 69, Issue:19 Topics: Animals; Apoptosis; Benzoxazines; Cell Line, Tumor; Cell Nucleolus; DNA Polymerase I; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Female; G-Quadruplexes; HL-60 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Nucleolin; Phosphoproteins; Quinolones; RNA-Binding Proteins; RNA, Ribosomal; Telomere; Transcription, Genetic; Xenograft Model Antitumor Assays	2009
A small-molecule inducer of the antioxidant response element. Chemistry & biology, 2010, May-28, Volume: 17, Issue:5 Topics: Antioxidants; Carcinogens; Cell Line; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasms; NF-E2-Related Factor 2; Protein Binding; Quinolones; Response Elements; Structure-Activity Relationship; Ubiquitination	2010
Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent. Marine drugs, 2010, Jul-13, Volume: 8, Issue:7 Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Female; Humans; Male; Mice; Neoplasms; Protein Binding; Pyrroles; Quinolones; Tissue Distribution; Xenograft Model Antitumor Assays	2010
Aminopyrimidoisoquinolinequinone (APIQ) redox cycling is potentiated by ascorbate and induces oxidative stress leading to necrotic-like cancer cell death. Investigational new drugs, 2012, Volume: 30, Issue:3 Topics: Adult; Ascorbic Acid; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Cytostatic Agents; Female; Humans; L-Lactate Dehydrogenase; Leukocytes; Male; Middle Aged; Necrosis; Neoplasms; Oxidation-Reduction; Oxidative Stress; Poly(ADP-ribose) Polymerases; Quinolones; Reactive Oxygen Species	2012
[The effects of Rebamipide and Polaprezinc mouthwash and uptake on mucositis induced by chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:13 Topics: Aged; Alanine; Antineoplastic Agents; Carnosine; Female; Humans; Male; Middle Aged; Mouthwashes; Mucositis; Neoplasms; Organometallic Compounds; Quality of Life; Quinolones; World Health Organization; Zinc Compounds	2011
New cytotoxic quinolone alkaloids from fruits of Evodia rutaecarpa. Fitoterapia, 2012, Volume: 83, Issue:4 Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Evodia; Fruit; Hep G2 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Phytotherapy; Plant Extracts; Quinolones	2012
Neoflavonoids and tetrahydroquinolones as possible cancer chemopreventive agents. Chemical biology & drug design, 2012, Volume: 80, Issue:4 Topics: Animals; Anticarcinogenic Agents; Aromatase Inhibitors; Cell Line, Tumor; Flavonoids; HEK293 Cells; Humans; Mice; Molecular Docking Simulation; NAD(P)H Dehydrogenase (Quinone); Neoplasms; NF-kappa B; Quinolones; Tumor Necrosis Factor-alpha	2012
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer research, 2013, Feb-15, Volume: 73, Issue:4 Topics: Acetylation; Allosteric Regulation; Animals; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Histone Deacetylases; Histones; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Models, Molecular; Neoplasms; Prodrugs; Protein Binding; Protein Structure, Tertiary; Quinolines; Quinolones; Repressor Proteins; RNA Interference; Signal Transduction; Thapsigargin; Tumor Microenvironment; Xenograft Model Antitumor Assays	2013
Predicting enhanced cell killing through PARP inhibition. Molecular cancer research : MCR, 2013, Volume: 11, Issue:1 Topics: 1-Naphthylamine; Animals; Antineoplastic Agents; Cell Death; DNA Damage; DNA Repair; Enzyme Inhibitors; Humans; Mice; Naphthalimides; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones	2013
Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra). Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:7 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disease Models, Animal; Humans; Mice; Neoplasms; Quinolones; Transplantation, Heterologous	2002
Mitogen-activated protein kinase routes as targets in the action of diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells. Molecular cancer therapeutics, 2002, Volume: 1, Issue:10 Topics: Animals; Anthracenes; Apoptosis; Cell Division; Doxorubicin; Enzyme Activation; Enzyme Inhibitors; HeLa Cells; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; K562 Cells; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; Mitogen-Activated Protein Kinases; Models, Chemical; NAD(P)H Dehydrogenase (Quinone); Neoplasms; p38 Mitogen-Activated Protein Kinases; Quinolones; Signal Transduction; Time Factors; Tumor Cells, Cultured	2002
Molecular targeting therapy for cancer: the Twelfth International Symposium of the Hiroshima Cancer Seminar, November 2002. Cancer science, 2003, Volume: 94, Issue:2 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials as Topic; DNA Repair; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Farnesyltranstransferase; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Proteins; Neoplasms; Quinolones; Xenograft Model Antitumor Assays	2003
In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients. Chemotherapy, 2004, Volume: 50, Issue:5 Topics: Anti-Bacterial Agents; Enterococcus; Fermentation; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Neutropenia; Quinolones; Staphylococcus; Streptococcus	2004
Farnesyltransferase inhibitors. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:3 Topics: Acylation; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Humans; Middle Aged; Neoplasm Proteins; Neoplasms; Protein Processing, Post-Translational; Quinolones; ras Proteins; Treatment Outcome	2005
Antibacterial prophylaxis in patients with cancer and neutropenia. The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1 Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacterial; Fever; Humans; Neoplasms; Neutropenia; Ofloxacin; Pseudomonas Infections; Quinolones	2006
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Molecular cancer therapeutics, 2006, Volume: 5, Issue:3 Topics: 1-Naphthylamine; Animals; Cricetinae; DNA; DNA Replication; Humans; Mice; Mice, Knockout; Naphthalimides; Neoplasms; Nucleic Acid Synthesis Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones; Radiation Tolerance; Radiation-Sensitizing Agents; S Phase; Tumor Cells, Cultured	2006
Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. Biochemical pharmacology, 2007, Jun-30, Volume: 74, Issue:1 Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; G2 Phase; Humans; Neoplasms; Paclitaxel; Quinolones; Tubulin; Tubulin Modulators; Vincristine	2007
The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. International journal of cancer, 2007, Nov-15, Volume: 121, Issue:10 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Farnesyltranstransferase; Female; Humans; Immunohistochemistry; Interferon-alpha; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasms; Phosphoserine; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Quinolones; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays	2007
Biological characterization of a novel antitumor quinolone. Cancer research, 1995, Feb-15, Volume: 55, Issue:4 Topics: Animals; Antineoplastic Agents; Bone Marrow; DNA, Neoplasm; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Lethal Dose 50; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Prodrugs; Quinolones; Transplantation, Heterologous; Tumor Cells, Cultured	1995
Bacteremia due to glucose non-fermenting gram-negative bacilli in patients with hematological neoplasias and solid tumors. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1996, Volume: 15, Issue:7 Topics: Adolescent; Adult; Alcaligenes; Anti-Bacterial Agents; Bacteremia; Bone Marrow Transplantation; Catheterization; Female; Glucose; Gram-Negative Aerobic Bacteria; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Neoplasms; Neutropenia; Pseudomonas putida; Quinolones; Retrospective Studies; Xanthomonas	1996
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. The Journal of antimicrobial chemotherapy, 1997, Volume: 39 Suppl B Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Neoplasms; Norfloxacin; Ofloxacin; Quinolones	1997
Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:11 Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Neoplasms; Quinolones	1999
In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients. The Journal of antimicrobial chemotherapy, 1990, Volume: 26, Issue:1 Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Quinolones	1990
In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients. The Journal of antimicrobial chemotherapy, 1989, Volume: 23, Issue:3 Topics: 4-Quinolones; Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Neoplasms; Quinolones	1989
Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1988, Volume: 7, Issue:5 Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Neoplasms; Quinolones; Staphylococcus; Streptococcus	1988